Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07277413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 21 to 23
  2. Study sites: 20 to 21
  3. Trial sites expanded: 17 → 20 locations Eligibility criteria expanded, about 39 words · Secondary endpoints: details revised at 3 of 15 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 39 words
    • Secondary endpoints: details revised at 3 of 15 entries
  4. Study sites: 16 to 17v10
  5. Study sites: 15 to 16v9
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 14 to 15v8
  2. Study sites: 12 to 14v7
  3. Study sites: 10 to 12 Eligibility criteria expanded, about 85 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 85 words

    See this version in full on ClinicalTrials.gov ↗

  4. Start date changed from estimate of Feb 28, 2026 to Mar 4, 2026v5
  1. Trial sites expanded: 3 → 10 locationsv4
  2. Start date: Dec 15, 2025 to Feb 28, 2026v3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3 · Secondary endpoints: details revised at 13 of 15 entriesv2 Show 2 more changesShow less
    • Study sites: 0 to 3
    • Secondary endpoints: details revised at 13 of 15 entries
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IDEAYA Biosciences
11 trials monitored
See all monitored trials
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Pancreatic Cancer
1,639 trials monitored
See 91 trials at risk
and 5 more diseases
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Trial Details
NCT Number NCT07277413
Lead Sponsor IDEAYA Biosciences
Conditions NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma +5 more
Enrollment 260 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov